Business context and reporting period
The supplied filing is Obalon Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2018—not a filing identified as Vyome Holdings, Inc. Obalon is a medical-device company commercializing its FDA-approved swallowable intragastric balloon system, with U.S. sales launched in January 2017. This issuer-name discrepancy should be verified before relying on the summary.
Financial performance and position
Amounts below are in millions of dollars unless otherwise indicated.
| Metric | Q1 2018 | Q1 2017 or prior period |
|---|---|---|
| Revenue | $1.346 | $1.472 |
| Gross profit / margin | $0.577 / 43% | $0.649 / 44% |
| Research and development expense | $2.639 | $2.400 |
| Selling, general and administrative expense | $10.006 | $5.940 |
| Operating loss | $(12.068) | $(7.691) |
| Net loss | $(12.126) | $(7.745) |
| Net loss per share, basic and diluted | $(0.71) | $(0.47) |
| Cash used in operating activities | $(10.602) | $(8.353) |
At March 31, 2018, cash and cash equivalents were $33.478 million, with no short-term investments, versus cash of $21.108 million and short-term investments of $23.292 million at December 31, 2017. Current assets were $39.085 million and current liabilities $9.110 million. The company had $10.0 million of term-loan principal outstanding, at a 6.25% variable rate, maturing in December 2020; principal payments were scheduled to begin in July 2018. Accumulated deficit was $123.5 million.
Changes versus the prior comparable period
- Revenue fell 9% year over year, despite higher unit volume; management attributed the decline to a lower average selling price from a change in customer mix. Lower U.S. sales were partly offset by higher Middle East distributor sales.
- Gross margin declined by about one percentage point. Cost of revenue remained approximately $0.8 million.
- SG&A increased $4.1 million, principally from $1.3 million of investigation-related legal, accounting and other costs, $1.0 million of additional marketing and advertising, $0.8 million of higher stock-based compensation, and increased payroll and related costs.
- Operating cash use increased by $2.2 million. The $22.9 million of net investing cash inflow primarily reflected maturities of short-term investments, not operating cash generation; cash increased by $12.4 million during the quarter.
Outlook, risks and unusual items
- Management expected existing cash and expected revenues to fund operations for twelve months from the filing date, but planned to seek additional debt or equity financing within three months to maintain its operating plan. Funding may not be available on acceptable terms or at all; spending cuts could delay or stop commercialization and development.
- The company expected continued losses and substantial spending on U.S. commercialization, sales and marketing, manufacturing capacity, research and development, and clinical work. It had not established revenue sufficient to cover operating costs.
- Revenue was highly concentrated: the Middle East distributor generated 63.1% of Q1 2018 revenue; the second-largest customer generated 14.0%. The largest customer also represented 22.0% of accounts receivable.
- A planned common-stock offering was terminated in January 2018 after a purported whistleblower complaint alleging improper revenue recognition. The audit committee’s investigation, conducted with outside counsel and a forensic accounting firm, concluded the allegations were without merit. The company reported that publicity, disruption and investigation costs could continue to affect operations and financing access.
- Two shareholder class actions filed in February 2018 allege misleading statements and omissions; one also alleges claims related to the IPO. The cases were at a preliminary stage, and the company intended to defend them. The company could not reasonably estimate potential underwriter fees, legal costs or trading losses related to termination of the offering.
- FDA major deficiency letters on the Obalon Navigation System and Obalon Touch Inflation System supplements required additional information or testing; approval and timing were uncertain. The company also cited manufacturing capacity, supplier, adoption, product-safety, competition and self-pay-demand risks.
- Disclosure controls were assessed as effective at a reasonable-assurance level; management reported no material change in internal control over financial reporting during the quarter. Adoption of ASC 606 had no material impact.
Most important facts for investors to verify
- Confirm the intended issuer: the filing names Obalon Therapeutics, Inc., while the request metadata names Vyome Holdings, Inc.
- Review subsequent financing, cash burn and runway, especially in light of management’s stated plan to seek financing within three months and the July 2018 start of loan principal payments.
- Track U.S. sales trends, customer concentration, average selling prices and the distributor’s contribution to revenue and receivables.
- Check outcomes and potential costs of the securities lawsuits and terminated-offering matter.
- Monitor FDA responses on the product supplements, manufacturing capacity, and any product safety or regulatory developments.